How MK-677 (Ibutamoren) Affects HbA1c

MK-677 elevates HbA1c through sustained glucose elevation:

1. Continuous GH secretion: MK-677's 24-hour half-life produces non-pulsatile GH elevation, driving persistent free fatty acid (FFA) release and the Randle cycle, which impairs glucose uptake in skeletal muscle.
2. Cumulative glucose exposure: HbA1c reflects average blood glucose over the preceding 2-3 months. Daily MK-677 use creates a persistent upward shift in average glucose that accumulates in the HbA1c reading.
3. Post-prandial effects: GH-mediated insulin resistance worsens both fasting and post-prandial glucose excursions. The post-prandial glucose spikes, often missed by fasting-only blood draws, contribute substantially to HbA1c.
4. Appetite-driven dietary effects: MK-677 significantly increases appetite. Higher caloric and carbohydrate intake amplifies the pharmacological glucose elevation, creating a compounding effect on HbA1c.

Standard dose (25 mg/day):

• HbA1c rises approximately 0.2% above placebo over 12 months (Nass et al., 2008)
• A shift from 5.3% to 5.5% is typical in metabolically healthy individuals
• Some subjects cross the pre-diabetic threshold (5.7%) during extended use

Lower doses (10-15 mg/day):

• HbA1c impact is proportionally smaller but still detectable with prolonged use
• Less appetite stimulation reduces the dietary contribution

Timeline: Unlike fasting glucose (which rises within 1-2 weeks), HbA1c changes lag by 2-3 months due to the red blood cell lifespan averaging 120 days. The first meaningful HbA1c reading should be taken at 3 months.

Baseline: Obtain HbA1c before starting MK-677. This establishes your personal reference point.

During use:

• HbA1c every 3 months (aligns with the marker's 2-3 month lookback window)
• Pair with fasting glucose and fasting insulin for a complete metabolic picture
• Calculate HOMA-IR at each check

Action thresholds:

• HbA1c below 5.7%: normal range, continue with monitoring
• HbA1c 5.7-6.4%: pre-diabetic range. Reduce dose, implement dietary controls, consider cycling off
• HbA1c 6.5% or above: diabetic threshold. Stop MK-677 and consult a physician

Preventing HbA1c drift:

• Start at 10-15 mg/day and titrate based on metabolic response
• Control carbohydrate intake, particularly in the evening when MK-677 appetite stimulation peaks
• Regular cardiovascular exercise improves insulin sensitivity and counteracts GH-mediated glucose elevation
• Berberine 500 mg 2-3x daily or metformin 500 mg/day if HbA1c trends upward despite lifestyle measures

If HbA1c enters pre-diabetic range (5.7-6.4%):

• Reduce MK-677 dose to the minimum effective amount
• Implement cycling (8 weeks on / 4 weeks off)
• Consider switching to pulsatile peptides (ipamorelin + CJC-1295) which carry lower metabolic risk
• If HbA1c does not improve within one cycle off, discontinue MK-677 and reassess

After stopping MK-677: HbA1c will take 2-3 months to reflect the improvement in glucose control, even though fasting glucose improves within 1-2 weeks.